0.00Open0.04Pre Close0 Volume4 Open Interest3.00Strike Price0.00Turnover0.00%IV-29.30%PremiumOct 18, 2024Expiry Date1.30Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma107.50Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Biora Therapeutics Stock Discussion
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting
Biora Therapeutics (Nasdaq: BIOR) announced that CEO Adi Mohanty will present the company's new 00-size BioJet™ device at the 14th Annual Partnership Opportunities in Drug Delivery (PODD) meeting in Boston, October 28–29, 2024. The company has successfully reduced the device size from 000 to 00 while increasing payload capacity, aligning with...
Biora Therapeutics Announces Positive Nasdaq Listing Decision
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that the company has been granted an extension to regain compliance with Nasdaq listing requirements.
"We shared with Nasdaq the upcoming company catalysts that we believe will drive significant value for shareholders, and we are pleased with their...
NaviCap™ Targeted Oral Delivery Platform and BT-600 in ulcerative colitis
Biora will present Phase 1 clinical trial data from the BT-600 program at the American College of Gastroenterology annual meeting in October, 2024.
Initiation of a Phase 1B clinical study in active ulcerative colitis patients is anticipated toward the end of 2024.
BioJet™ Systemic Oral Delive...
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
Biora Therapeutics (Nasdaq: BIOR) presented supplemental data from the Phase 1 trial of BT-600, an orally administered drug-device combination for ulcerative colitis treatment, at a virtual KOL event. The trial results demonstrated that BT-600, using Biora's NaviCap™ platform, successfully delivered tofacitinib directly to the colon, achieving higher ti...
No comment yet